- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01344707
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Köln, Germany
- Universiätsklinikum Köln
-
Stuttgart, Germany
- Robert-Bosch-Krankenhaus
-
Würzburg, Germany
- Universitätsklinikum Würzburg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients, age ≥ 18 years.
- Patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM),Myelodysplastic Syndrome (MDS) or malignant lymphoma which are relapsed and/or refractory to standard therapy or for which no standard therapy exists. Patients who are not eligible for curative stem cell transplantation or patients who have refused or are not eligible for frontline (chemo-) therapy may also be included.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
- Patients must have a live expectancy of 12 weeks or more.
- Patients must have adequate bone marrow reserve as well as adequate renal and hepatic function and serum electrolytes within a clinically acceptable range.
- Patients must have recovered from any treatment-related toxicities (to Grade 0 or 1 according to Common Terminology Criteria for Adverse Events (CTCAE); except for alopecia, fatigue and Grade 1 neurotoxicity) prior to registration.
Exclusion Criteria:
- Patients who have received previous treatment with an HDAC inhibitor.
- Patients with any gastrointestinal disorder that could interfere with the absorption of 4SC-202
- Patients who are unable to take oral medication.
- Patients with a history of other malignancies unless having undergone definitive treatment more than 5 years prior to entry into the study and without evidence of recurrent malignant disease, excluding patients with basal cell carcinoma of the skin; superficial carcinoma of the bladder; carcinoma of the prostate with a current prostate specific antigen (PSA) value of < 0.1 ng/ml; or cervical intraepithelial neoplasia.
- Patients with a history of, who were treated for, or who are suspected of having, hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Patients suspected of having any of these conditions should undergo appropriate evaluations prior to being enrolled in the study.
- Patients with precedent anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the last two weeks or a longer period depending on the known PK characteristics of the agents used.
- Patients with history or current evidence of clinically relevant allergies or idiosyncrasy to drugs (especially of similar chemical composition to the study drug) or food.
- Patients with symptomatic brain metastases/central nervous system (CNS) involvement.
- Patients with significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure (New York Heart Association (NYHA) Class III or IV) related to primary cardiac disease, a condition requiring anti-arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the trial entry.
- Patients with a marked baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc interval > 450 msec (Grade 1 CTCAE); Long-QT-Syndrome; the required use of concomitant medication on 4SC-202 dosing days that may cause Torsade de Pointes.
- Therapy with agents known to prolong the QT interval, such as certain antibiotics (i.e. erythromycin, clarithromycin), antidepressants (i.e. doxepin, amitryptilin) or neuroleptics (i.e. haloperidol, clozapin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of Dose Limiting Toxicities of 4SC-202
Time Frame: 6 weeks
|
6 weeks
|
|
Determination of Safety of 4SC-202
Time Frame: 6 weeks
|
The safety and tolerability will be determined by occurrence of adverse events (AEs), vital signs (VS) [body temperature, weight, blood pressure (BP), pulse rate], electrocardiogram (ECG), performance status and clinical laboratory parameters.
|
6 weeks
|
Determination of Pharmacokinetic Profile of 4SC-202
Time Frame: 3 weeks
|
The plasma concentrations of 4SC-202 will be determined at the following time-points: Cycle 1 Day 1: Pre-dose, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 8 h, 24 h p.a. Cycle 1 Day 5: Pre-dose, 0.5 h, 1h, 2h Cycle 1 Day 14: Pre-dose, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 8 h, 24 h p.a. Cycle 2 Day 1: Pre-dose, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 8 h, 24 h p.a. using AUC0-infinity, AUClast, Cmax, tmax, t1/2, CL/F |
3 weeks
|
Determination of Maximum Tolerated Dose of 4SC-202
Time Frame: 6 weeks
|
6 weeks
|
|
Determination of Tolerability of 4SC-202
Time Frame: 6 weeks
|
The safety and tolerability will be determined by occurrence of adverse events (AEs), vital signs (VS) [body temperature, weight, blood pressure (BP), pulse rate], electrocardiogram (ECG), performance status and clinical laboratory parameters.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of potential anticancer activity of 4SC-202
Time Frame: 6 weeks
|
The assessment will be performed by assessment of tumor response, duration of response and progression free survival
|
6 weeks
|
Histone deacetylase (HADAC) inhibition in peripheral mononuclear cells
Time Frame: 6 weeks
|
6 weeks
|
|
Histone acetylation in peripheral mononuclear cells
Time Frame: 6 weeks
|
6 weeks
|
|
Gene expression analysis in peripheral blood
Time Frame: 6 weeks
|
6 weeks
|
|
Cytokine and miRNA levels in plasma
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andreas Engert, Prof. MD, Universitätsklinikum Köln
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4SC-202-1-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hematologic Malignancies
-
Suzhou Junjing BioSciences Co., Ltd.RecruitingAdvanced Solid Tumors | Advanced Hematologic MalignanciesChina
-
PfizerTerminatedAdvanced Non-Hematologic MalignanciesUnited States, United Kingdom
-
PfizerCompletedAdvanced Non-Hematologic MalignanciesUnited Kingdom
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Non-hematologic MalignanciesUnited States, Canada
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors and Hematologic MalignanciesChina
-
Ascentage Pharma Group Inc.RecruitingAdvanced Solid Tumors or Hematologic MalignanciesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Malignancies | Hematologic MalignanciesUnited States
-
Ospedale Santa Croce-Carle CuneoUnknownAdvanced Haematological Malignancies | High Risk Haematological MalignanciesItaly
-
iOMEDICO AGBristol-Myers Squibb; Roche Pharma AGCompletedAdvanced Solid Tumors or Hematologic MalignanciesGermany
-
Anand B. KarnadCompletedAdvanced B-cell Lymphoid MalignanciesUnited States
Clinical Trials on 4SC-202
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
4SC AGCompletedMalignant MelanomaGermany, Italy
-
4SC AGCompletedMalignant Lymphomas | Advanced and Incurable Solid TumorsGermany
-
4SC AGCompleted
-
4SC AGCompletedInflammatory Bowel Disease (IBD)Germany, Bulgaria, Romania
-
4SC AGActive, not recruitingLymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary SyndromeAustria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
-
4SC AGCompletedAdvanced Colorectal CarcinomaGermany
-
Devalingam MahalingamGenSpera, Inc.No longer availableHepatocellular Carcinoma
-
GenSpera, Inc.WithdrawnProstate Cancer.United States
-
Immune-Onc TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)RecruitingCMML | AML With Monocytic DifferentiationUnited States